Eli Lilly

Eli Lilly and Company (NYSE: LLY) has announced its plan to issue €600 million in aggregate principal in the amount of 0.50% notes with 12-year maturity as part of its Environmental, Social and Governance (ESG) strategy. In May, the company announced that it had updated its Environmental, Social and Governance (ESG) strategy, bolstering its investment…

Eli Lilly (NYSE:LLY) is looking for nominations for its inaugural Leonard Award series, which highlights advances in diabetes management. The company will select five winners and donate $100,00 to the non-profit Life for a Child, which provides medicines and supplies to children and youth with type 1 diabetes in developing countries.  Lilly is launching the award program…

In an SEC filing, Eli Lilly (NYSE:LLY.N) revealed that it had received a subpoena from the U.S. Department of Justice connected to a manufacturing site in New Jersey that produces bamlanivimab, one of two COVID-19 monoclonal antibodies it produces. The plant also produces the blockbuster Trulicity and cancer drugs. Lilly did not state which types…

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.  Now ranked eighth overall, the pharma industry came in just ahead of…

Eli Lilly (NYSE:LLY) announced that it had amended purchase agreements with the U.S. government to prioritize using two monoclonal antibodies — bamlanivimab and etesevimab — in tandem. In March, the U.S. government announced that it would stop using bamlanivimab alone, given its reduced efficacy against some SARS-CoV-2 variants. But pairing anti-SARS-CoV-2 monoclonal antibodies together can offer more…

The spread of SARS-CoV-2 variants has convinced the U.S. government to stop using Lilly’s COVID-19 monoclonal antibody therapy bamlanivimab when used alone. The U.S. government will continue using bamlanivimab when paired with etesevimab, another monoclonal antibody. The government pointed to the rising number of SARS-CoV-2 variants across the country as the reasoning behind the decision.…

Eli Lilly (NYSE:LLY) has announced that its chief financial officer Joshua Smiley has resigned. An independent investigation with external counsel discovered “consensual though inappropriate” communications between Smiley and a number of employees, according to a Lilly statement.  Lilly has installed a replacement, Anat Ashkenazi, who has worked at the company for almost 20 years. “We are…

Eli Lilly (NYSE:LLY) shares ticked up this morning on fourth-quarter results that beat the consensus forecast. The Indianapolis-based company posted profits of $2.1 billion or $2.32 per share, on sales of $7.4 billion for the three months ended Dec. 31, 2020, for a 41.5% bottom-line gain on sales growth of 21.7%. Adjusted to exclude one-time items,…

The FDA has approved the first generic of glucagon for injection for severe hypoglycemia, which can afflict some patients with diabetes.  FDA has also indicated glucagon to facilitate diagnosis in radiological exams of the digestive tract as the drug can reduce intestinal motility.  Glucagon is a hormone that, when released, triggers the liver to release…

CVS Health (NYSE:CVS), the parent of the retail pharmacy chain CVS Pharmacy, Aetna and other brands, has committed to partnering with the Trump administration to administer Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab). The company will administer the intravenous therapy to high-risk patients in their homes or long-term care facilities.  In the pilot program, CVS will administer 1,000…